🇺🇸 FDA
Patent

US 8242074

Modulation of the amount or function of pathogenic CD14+CD16+ monocytes

granted A61KA61K2039/505A61P

Quick answer

US patent 8242074 (Modulation of the amount or function of pathogenic CD14+CD16+ monocytes) held by XBIOTECH INC. expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
XBIOTECH INC.
Grant date
Tue Aug 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61P, A61P1/04, A61P19/02